9-ING-41 + cyclophosphamide + topotecan

**9-ING-41 + cyclophosphamide + topotecan** is an experimental combination therapy consisting of three pharmacologic agents: - **9-ING-41**: a first-in-class, intravenously administered small molecule inhibitor of glycogen synthase kinase-3 beta (**GSK-3β**), which regulates multiple cellular processes including metabolism, proliferation, and apoptosis. 9-ING-41 acts as a potent, selective GSK-3β inhibitor with demonstrated antitumor activity in preclinical and early clinical studies. Its proposed mechanisms include inhibition of GSK-3β-driven pathways (e.g., NF-κB, c-Myc, beta-catenin), induction of apoptosis, cell cycle arrest, and reversal of chemotherapy resistance, particularly in cancer cells showing NF-κB pathway activation[1][2][3]. - **Cyclophosphamide**: a classic alkylating agent (small molecule chemotherapy) used in a wide range of malignancies, acting primarily by crosslinking DNA and inducing cell death. - **Topotecan**: a topoisomerase I inhibitor (small molecule chemotherapy) that prevents DNA unwinding and replication in cancer cells, leading to cytotoxicity. This combination is being evaluated for potential synergistic activity in overcoming chemoresistance and enhancing tumor cell apoptosis in various advanced cancers, primarily in early-phase clinical research[1][3][2].